Kindred Biosciences has big plans to apply human medicine to our kindred spirits, our pet dogs. The company is creating pharmaceuticals that were originally developed for human use and reformulating them for animals. It has three product candidates in development – CereKin, for osteoarthritis pain and inflammation in dogs; AtoKin, for atopic dermatitis in dogs; and SentiKin, for post-operative pain in dogs. (It hopes to have these pharmaceuticals approved in 2015.) In addition, the company has seven other early-stage drugs in development that would treat various ailments in dogs, cats, and horses. Founded in 2012 by CEO Richard Chin, Kindred Biosciences went public in 2013, raising $52 million in its IPO.